Provided by Tiger Fintech (Singapore) Pte. Ltd.

BridgeBio Pharma, Inc.

31.37
-2.7000-7.92%
Post-market: 31.03-0.3400-1.08%17:35 EDT
Volume:4.02M
Turnover:128.35M
Market Cap:5.97B
PE:-10.90
High:33.89
Open:33.37
Low:30.86
Close:34.07
Loading ...

BridgeBio price target raised to $46 from $45 at BofA

TIPRANKS
·
28 Feb

BridgeBio Pharma (BBIO): Among the Best Performing Mid Cap Stocks to Buy According to Analysts

Insider Monkey
·
27 Feb

BUZZ-U.S. STOCKS ON THE MOVE-Cheesecake Factory, SiriusPoint, Arcutis Biosciences

Reuters
·
27 Feb

BridgeBio Pharma Prices $500 Million Convertible Senior Notes Offering

MT Newswires Live
·
26 Feb

BridgeBio Prices Offering of $500 Million Convertible Senior Notes Due 2031 to Refinance Senior Secured Debt

THOMSON REUTERS
·
26 Feb

BridgeBio Pharma Inc - Expects Net Proceeds of $489.5 Million From Notes Sale

THOMSON REUTERS
·
26 Feb

Press Release: BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

Dow Jones
·
26 Feb

Stock Track | BridgeBio Pharma Plunges 5.71% on $500 Million Convertible Debt Offering to Refinance Debt

Stock Track
·
25 Feb

Stock Track | BridgeBio Pharma Plunges 5.16% in Pre-market on $500 Million Convertible Bond Offering

Stock Track
·
25 Feb

BUZZ-BridgeBio falls after announcing $500 mln convertible to refinance debt

Reuters
·
25 Feb

Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), Madrigal Pharmaceuticals (MDGL)

TIPRANKS
·
25 Feb

BRIEF-BridgeBio Pharma To Offer $500 Million Convertible Senior Notes Due 2031

Reuters
·
25 Feb

BridgeBio Pharma Inc - Option to Purchase Additional $75 Million Notes

THOMSON REUTERS
·
25 Feb

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

THOMSON REUTERS
·
25 Feb

BridgeBio Pharma Inc - Proceeds to Repay and Terminate Financing Agreement

THOMSON REUTERS
·
25 Feb

BridgeBio price target raised to $52 from $49 at Scotiabank

TipRanks
·
22 Feb

BridgeBio Pharma Price Target Maintained With a $95.00/Share by Cantor Fitzgerald

Dow Jones
·
22 Feb

BridgeBio Pharma Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
21 Feb

BridgeBio Pharma (BBIO) Gets a Buy from Scotiabank

TIPRANKS
·
21 Feb

BridgeBio Pharma Q4 EPS $(1.40) Misses $(1.14) Estimate, Sales $5.88M Beat $3.48M Estimate

Benzinga
·
20 Feb